Traws Pharma Inc (NASDAQ:TRAW) does about 11.86K shares in volume on a normal day but saw 28298849 shares change hands in the recent trading day. The company now has a market cap of 35.79M USD. Its current market price is $12.57, marking an increase of 150.40% compared to the previous close of $5.02. The 52 week high reached by this stock is $19.94 whilst the lowest price level in 52 weeks is $4.06.
Traws Pharma Inc (TRAW) has a 20-day trading average at $5.29 and the current price is -36.95% off the 52-week high compared with 209.61% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.11 and its 200-day simple moving average is $11.07. If we look at the stock’s price movements over the week, volatility stands at 21.54%, which decreases to 10.53% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 87.38 to suggest the stock is overbought.
The consensus objective for the share price is $6.00, suggesting that the stock has a potential downside of -109.5% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 01, 2022 when Ladenburg Thalmann initiated the stock to “Buy” and issued a price target of $7. H.C. Wainwright reiterated its price target at $6-$7.50.
The current price level is 137.63%, 146.16%, and 28.17% away from its SMA20, SMA50, and SMA200 respectively, with the TRAW price moving below the 50-day SMA on current market day. Traws Pharma Inc (TRAW) stock is up 167.58% over the week and 178.71% over the past month. Its price is 34.87% year-to-date and 43.27% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year. Expected sales for next quarter are $60k, which analysts say will come at $230k for the current fiscal year and next year at $230k. In addition, estimates put the company’s current quarterly revenue at an average of $60k.
To reach the target analysts have set, the stock logically needs to shrink -109.5 percent from here.
Outstanding shares total 3.03M with insiders holding 10.04% of the shares and institutional holders owning 21.40% of the company’s common stock. The company has a return on equity of -2255.45%. The beta has a value of 1.12. Price to sales ratio is 155.62.
